

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-072024-000987

Date: 14/08/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli)
- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT

Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT

Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Response

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Yes

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

Dostarlimab (Jemperli)	< 5
Dostarlimab (Jemperli) and Chemotherapy	< 5
Hormone Therapy (Progestrone or Letrozole)	The Trust does not hold this information in a reportable format. When information is not in a reportable format, The ICO guidance clearly states “FOIA only applies to information that a public authority already holds in recorded form at the time of a request. If you don’t hold a particular piece of information that someone has asked for, you don’t have to create it’.
Pembrolizumab (Keytruda) Monotherapy	0
Lenvatinib + Pembrolizumab (Lenvatinib + Keytruda)	0
Platinum-based Chemotherapy (Monotherapy or combination with Taxanes, Anthracyclines, Cyclophosphamide)	6
Any other SACT	< 5

The Trust does not publish numbers lower than 5 as this could lead to the identification of the person(s) involved and cause distress to families and friends. the number of patients treated for endometrial cancer in the past 3 months requested is less than 5, therefore Section 40(2) of the Freedom of Information Act has been applied.

Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

6

Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

Dostarlimab (Jemperli) and Chemotherapy	1
---	----------

Hormone Therapy (Progesterone or Letrozole)	The Trust does not hold this information in a reportable format. When information is not in a reportable format, <i>The ICO guidance clearly states “FOIA only applies to information that a public authority already holds in recorded form at the time of a request. If you don’t hold a particular piece of information that someone has asked for, you don’t have to create it”.</i>
Platinum-based Chemotherapy (Monotherapy or combination with Taxanes, Anthracyclines and Cyclophosphamide)	6
Any other SACT	0

Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

The Trust is not participating in trials.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell’s Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team
The Dudley Group NHS Foundation Trust**